JERUSALEM, May 31, 2018 /PRNewswire/ --
Intec Pharma Ltd. (NASDAQ: NETC) (TASE: NTEC) ("Intec" or "the
Company") today announces that Company management will participate
at the upcoming Jefferies 2018 Healthcare Conference taking place
June 5 - 8, 2018 in New York City. Jeffrey
A. Meckler, Intec Pharma's Vice Chairman and Chief Executive
Officer, will present a corporate overview on June 7th at 2:30 p.m. Eastern time.
Mr. Meckler's presentation will be webcast live and will be
accessible through the Events section of Intec Pharma's website,
where it will also be archived for a period of time.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is being developed for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients, and
AP-cannabinoids, an Accordion Pill to deliver either or both of the
primary cannabinoids contained in Cannabis sativa, cannabidiol
(CBD) and tetrahydrocannabinol (THC) for various indications
including low back neuropathic pain and fibromyalgia.
For more information, visit http://www.intecpharma.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company's control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company's filings with the Securities and Exchange Commission,
and include the following: the company's ability to develop and
commercialize its product candidates and obtain additional
financing necessary therefor; the length, cost and uncertain
results of the company's clinical trials; including uncertainty
regarding the Company's ability to enroll the required number of
patients therein; the potential of adverse side effects, other
safety risks, or legal prohibitions on the use of certain products
in certain jurisdictions that could preclude the approval of the
company's drug candidates; the availability of reimbursement from
government authorities and health insurance companies for the
company's products; the impact of product liability lawsuits; and
the influence of extensive and costly government regulation.
Intec Pharma Investor Contact:
Anne Marie Fields
VP-Corporate Communications & Investor Relations
+1-646-200-8808
amf@intec-us.com
SOURCE Intec Pharma